Effects of Hepatic Ultrasound on Metabolic Homeostasis

Yale University37 enrolled

Overview

The purpose of this study is to define the effect of ultrasound exposure of the liver in the region of the porta hepatis on glucose homeostasis and insulin resistance in healthy subjects.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy Insulin Resistance

Interventions

UltrasoundPROCEDURE

To determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels. To also determine whether porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 18 - 60 years of age * Aim 1: Healthy lean men and women, BMI\<24 kg/m2, with normal fasting glucose (blood glucose between 60 and 100mg/dl and normal glucose tolerance on OGTT (blood glucose \<140 mg/dl at 2 hours post glucose challenge) at the screening visit. * Aim 2: Overweight and obese men and women, BMI 25 - 35 kg/m2 Exclusion Criteria: * Type 1 and type 2 diabetes * Surgery in the past 90 days * Previous surgery of the spleen or splenectomy, esophagus, lungs, stomach, duodenum, or liver * Recent traumatic injury, including intra-cerebral hemorrhage and visceral injury * End stage renal disease and/or uremia * Active malignancy * Previous leukemia and/or lymphoma * Human immunodeficiency virus infection or AIDS * Rheumatoid arthritis or other immune-mediated diseases (e.g. inflammatory bowel disease) * Arrhythmias, including but not limited to, atrial fibrillation, atrial flutter, bradycardia, ventricular arrhythmias, and A-V block * Implanted pacemaker or cardioverter/defibrillator (AICD) * History of stable or unstable angina, myocardial infarction, angioplasty or coronary arterial by-pass grafting surgery * History of stroke or TIA * History of deep venous thrombosis (DVT) and/or pulmonary embolism (PE) * Previous episodes of pancreatitis * Spinal disorders * Chronic pain syndromes * History of thrombosis or bleeding disorders * Stage III-IV pressure ulcers * Sickle cell anemia or other anemia syndromes * Monocytosis * Thrombocytopenia * Diagnosed with fever of unknown origin (FUO) * Previously or currently implanted vagus nerve stimulator * Previously or currently implanted spinal cord stimulator * Other chronically-implanted electronic medical device * History of seizures * History of cancer * Individuals who have taken any of the following medications within two weeks of receiving ultrasound delivery: anti-coagulant, anti-platelet, anti-inflammatory, immunosuppressive agents, alpha and/or beta adrenoceptor blocking agents, anti-seizure medications, anti-diabetic medication * Individuals with a substance abuse problem * Pregnant women * Ascites detected in the abdomen that may effect delivery of shear wave elastroghapy pulse

Locations (1)

Yale-New Haven Hospital

New Haven, Connecticut, United States

Outcomes

Primary Outcomes

Insulin Resistance

Change in OGTT measurements after Hepatic Ultrasound

Time frame: 1 week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.